Dicerna Pharmaceuticals reported $616.49M in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acceleron Pharma XLRN:US $ 717.77M 19.84M
Agenus AGEN:US $ 92.85M 42.81M
Alnylam Pharmaceuticals ALNY:US $ 2725.16M 255.08M
Amgen AMGN:US $ 19099M 2200M
Arrowhead Research ARWR:US $ 525.96M 60.8M
Biogen BIIB:US $ 7183.7M 464.2M
Bluebird Bio BLUE:US $ 903.53M 194.01M
Dicerna Pharmaceuticals DRNA:US $ 616.49M 21.99M
Exelixis EXEL:US $ 1593.25M 158.98M
Gilead Sciences GILD:US $ 14498M 1220M
GlaxoSmithKline GSK:LN 17.57B 958M
Immunogen IMGN:US $ 274.4M 45.18M
Intercept Pharmaceuticals ICPT:US $ 493.1M 5.54M
Intrexon XON:US $ 156.68M 12.57M
Karyopharm Therapeutics KPTI:US $ 273.5M 17.99M
Macrogenics MGNX:US $ 367M 7.72M
Mirati Therapeutics MRTX:US $ 1278.09M 25.42M
Regeneron Pharmaceuticals REGN:US $ 13337.6M 3282.5M
Regulus Therapeutics RGLS:US $ 46.31M 9.78M
Ultragenyx Pharmaceutical RARE:US $ 949.49M 121.44M